Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (HEAD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05361382 |
|
Recruitment Status :
Recruiting
First Posted : May 4, 2022
Last Update Posted : November 7, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer Disease | Drug: 18F-Flortaucipir radiopharmaceutical Drug: 18F-MK-6240 radiopharmaceutical Drug: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir) | Phase 1 |
This is a longitudinal, multi-site, non-randomized study in which the participants will undergo Flortaucipir and MK-6240 PET scans at baseline and approximately at 18-month follow-up. At each time point, participants will also have an amyloid-β PET scan, magnetic resonance imaging, detailed cognitive tests, and a blood draw for biomarker quantification. The main objectives of this study are standardizing tau PET tracers' outcomes and comparing their performance.
To accomplish our objectives, the investigators propose the following specific aims:
In Aim 1, investigators will standardize tau PET processing methods, convert the tracers to a common scale, compare associations with amyloid-β, atrophy, and cognition, and compare/harmonize Braak staging assessments between tau tracers using cross-sectional data.
In Aim 2, investigators will ascertain the optimal processing method for longitudinal analysis and compare longitudinal changes in tau accumulation obtained with the tau PET radiopharmaceuticals and their associations with changes in amyloid-β, atrophy, and cognition.
In Exploratory Aim 3, investigators will compare cross-sectional and longitudinal Flortaucipir and MK-6240 estimates with plasma phosphorylated tau concentrations.
This study will produce a benchmark dataset to develop methods for tau PET quantification and harmonization.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 620 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers |
| Actual Study Start Date : | November 23, 2021 |
| Estimated Primary Completion Date : | May 31, 2027 |
| Estimated Study Completion Date : | May 31, 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Individuals across the aging and Alzheimer's disease (AD) spectrum
Approximately 620 individuals (40 young healthy, 280 cognitively unimpaired older, 200 mild cognitive impairment, and 100 Alzheimer's disease dementia) will be enrolled in the HEAD study.
|
Drug: 18F-Flortaucipir radiopharmaceutical
Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
Other Name: 18F-AV-1451, 18F-T807, Tauvid Drug: 18F-MK-6240 radiopharmaceutical MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical. Drug: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir) The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques. Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical. |
- Cross-sectional tau PET uptake values [ Time Frame: 2 years from enrollment ]Compare/harmonize cross-sectional tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240.
- Longitudinal change in tau PET uptake values over 18 months [ Time Frame: 5 years from enrollment ]Compare/harmonize change in tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 between baseline and 18-month follow-up assessments.
- Associations of tau PET uptake values with amyloid-β PET uptake values [ Time Frame: 5 years from enrollment ]Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with amyloid-β deposition measurements (SUVR).
- Associations of tau PET uptake values with measures of cognition [ Time Frame: 5 years from enrollment ]Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with cognitive measures assessed from neuropsychological evaluation.
- Associations of tau PET uptake values blood biomarkers [ Time Frame: 5 years from enrollment ]Compare the effect size of the associations of tau deposition measurements (standardized uptake value ratio (SUVR)) obtained with Flortaupicir and MK-6240 with blood-based biomarkers of tau.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- Have an informant who will be able to provide an independent evaluation of functioning.
- Willing and capable of undergoing repeated MR/PET imaging.
- Fluent in a language approved by the coordinating center.
- At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.
Exclusion criteria:
- Inability to provide informed consent by self or by proxy.
- Pregnant or breastfeeding women.
- Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05361382
| Contact: Tharick Pascoal, MD PhD | 412-586-9012 | pascoal-research@upmc.edu |
| United States, California | |
| Lawrence Berkeley National Laboratory | Recruiting |
| Berkeley, California, United States, 94720 | |
| Contact: Suzanne Baker, PhD | |
| University of California San Francisco | Recruiting |
| San Francisco, California, United States, 94143 | |
| Contact: David Soleimani-Meigooni, MD | |
| United States, Minnesota | |
| Mayo Clinic | Not yet recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Val Lowe, MD | |
| United States, Missouri | |
| Washington University in St. Louis | Recruiting |
| Saint Louis, Missouri, United States, 63130 | |
| Contact: Brian A Gordon, PhD | |
| United States, Pennsylvania | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15260 | |
| Contact: Tharick Pascoal, MD PhD | |
| United States, Rhode Island | |
| Brown University | Recruiting |
| Providence, Rhode Island, United States, 02912 | |
| Contact: Hwamee Oh, PhD | |
| United States, Texas | |
| Houston Methodist Neurological Institute | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Maria B Pascual, PhD | |
| Canada, Quebec | |
| McGill University Research Centre for Studies in Aging | Recruiting |
| Montréal, Quebec, Canada, H4H1V3 | |
| Contact: Pedro Rosa-Neto, MD, PhD | |
| Spain | |
| Sant Pau Biomedical Research Institute | Not yet recruiting |
| Barcelona, Spain, 08025 | |
| Contact: Juan Fortea, MD, PhD | |
| Principal Investigator: | Tharick Pascoal, MD PhD | University of Pittsburgh |
| Responsible Party: | Tharick Pascoal, Assistant Professor, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT05361382 |
| Other Study ID Numbers: |
STUDY22020056 R01AG073267 ( U.S. NIH Grant/Contract ) |
| First Posted: | May 4, 2022 Key Record Dates |
| Last Update Posted: | November 7, 2023 |
| Last Verified: | November 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data from this research will be shared with other researchers pursuant to the 02/26/2003 "NIH Final Statement on Sharing Research Data". To protect participants' rights and confidentiality, identifiers will be removed from the data before they are shared. The board of PIs has primary oversight of the HEAD study resource sharing plan and will review all issues related to internal and external requests for HEAD data. Raw PET and MR data will be uploaded by clinical sites after acquisitions, whereas processed PET and MR data will be uploaded after completion of the baseline visit and after completion of the 18-month follow-up visit. Demographics, results from cognitive tests, Aβ status, tau Braak staging, and plasma assay results will also be available through the LONI platform. |
| Time Frame: | Data from baseline and follow-up assessments will be available for sharing after the completion of the respective study visits. |
| Access Criteria: | Researchers will be able to download data upon request to the PIs. Data sharing requests will be overseen by the study and site PIs. |
| URL: | http://www.loni.usc.edu/ |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Tau PET Neurofibrillary tangles Alzheimer's disease Tauopathies Biomarkers |
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies |
Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Radiopharmaceuticals Molecular Mechanisms of Pharmacological Action |